GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Biomarin Pharmaceutical Inc. (BMRN) [hlAlert]

Rating:
Equal Weight
BMRN
up 237.43 %

Biomarin Pharmaceutical Inc. (BMRN) rated Equal Weight with price target $76 by Barclays

Posted on: Wednesday,  Feb 19, 2014  3:25 PM ET by Barclays

Barclays rated Equal Weight Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) on 02/19/2014. Previously Barclays rated Overweight Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) on
08/24/2012., when the stock price was $38.79. Since then, Biomarin Pharmaceutical Inc. has gained 237.43% as of 11/25/2015's recent price of $130.89.
If you would have followed the previous Barclays's recommendation on BMRN, you would have gained 237.43% of your investment in 1188 days.

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.

Barclays
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/19/2014 3:25 PM Buy
None
76.35 76.00
as of 10/17/2014
1 Week down  -0.49 %
1 Month up  3.28 %
3 Months up  26.29 %
1 YTD up  0.14 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/10/2014 1:25 PM Buy
None
69.45 73.00
4/3/2013 12:25 PM Buy
None
61.95 70.00
11/6/2012 2:25 PM Buy
None
48.73 54.00
8/24/2012 1:25 PM Buy
None
38.79 46.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy